Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCEH1 | Q6PIU2 | 6/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16965115 | 0.92 | RAB9A (0.60) | NCEH1RAB9ATSHRPKMNPC1 | |
| SCHEMBL13034567 | 0.82 | KMT2A (0.49) | CA12CA1CA2CA4CA7 | |
| SCHEMBL29728586 | 0.82 | NCEH1 (0.54) | NCEH1RAB9ATSHRPKMNPC1 | |
| SCHEMBL16965297 | 0.82 | NCEH1 (0.54) | NCEH1RAB9ATSHRPKMNPC1 | |
| O-Tolyl Dimethylcarbamate SCHEMBL8927621 | 0.80 | NCEH1 (0.56) | NCEH1RAB9ATSHRPKMNPC1 | |
| SCHEMBL12086299 | 0.79 | HSD17B10 (0.62) | RAB9ATSHRNPC1CA12CA1 | |
| SCHEMBL18375785 | 0.79 | SLC6A3 (0.65) | NCEH1TSHRLMNA | |
| SCHEMBL12988419 | 0.79 | BCHE (0.54) | CA12CA1CA2CA4CA7 | |
| SCHEMBL12084058 | 0.79 | CA12 (0.46) | CA12CA1CA2CA4CA7 | |
| SCHEMBL11299389 | 0.79 | L3MBTL1 (0.56) | NCEH1RAB9ATSHRPKMNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281476-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| WO-2007076070-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281476-A1 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | NCEH1 778/4885RAB9A 1944/4885TSHR 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.